Phase Ib study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with advanced or metastatic solid tumors

We conducted a phase I, multicenter, open-label, dose-finding, and expansion study to determine the safety and preliminary efficacy of eprenetapopt (APR-246) combined with pembrolizumab in patients with advanced/metastatic solid tumors (ClinicalTrials.gov NCT04383938). For dose-finding, requirements...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	ESMO open 2022-10, Vol.7 (5), p.100573-100573, Article 100573
Hauptverfasser:	Park, H., Shapiro, G.I., Gao, X., Mahipal, A., Starr, J., Furqan, M., Singh, P., Ahrorov, A., Gandhi, L., Ghosh, A., Hickman, D., Gallacher, P.D., Wennborg, A., Attar, E.C., Awad, M.M., Das, S., Dumbrava, E.E.
Format:	Artikel
Sprache:	eng
Schlagworte:	clinical trial eprenetapopt Original Research p53 pembrolizumab solid tumors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!